New hope for breast cancer patients in critical condition
NCT ID NCT07203729
Summary
This study is testing whether a new drug called Trastuzumab Rezetecan (SHR-A1811) works better than standard chemotherapy for people with a severe, fast-spreading type of breast cancer that is causing organ failure. About 184 participants with this advanced cancer will receive either the new drug or a chemotherapy chosen by their doctor. The main goal is to see if the new drug can slow the cancer's growth and extend life without causing severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-LOW UNRESECTABLE/METASTATIC BREAST CANCER COMPLICATED WITH VISCERAL CRISIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.